These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38214201)

  • 1. Lipid-based mesoporous silica nanoparticles: a paradigm shift in management of pancreatic cancer.
    Bellapu KK; Joga R; Kannan BR; Yerram S; Varpe P; Mergu T; Vasu PY; Srivastava S; Kumar S
    Pharm Pat Anal; 2023 Nov; 12(6):261-273. PubMed ID: 38214201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
    Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
    ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer.
    Liu X; Situ A; Kang Y; Villabroza KR; Liao Y; Chang CH; Donahue T; Nel AE; Meng H
    ACS Nano; 2016 Feb; 10(2):2702-15. PubMed ID: 26835979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility.
    Tarn D; Ashley CE; Xue M; Carnes EC; Zink JI; Brinker CJ
    Acc Chem Res; 2013 Mar; 46(3):792-801. PubMed ID: 23387478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-Delivery of Gemcitabine and Honokiol by Lipid Bilayer-Coated Mesoporous Silica Nanoparticles Enhances Pancreatic Cancer Therapy via Targeting Depletion of Tumor Stroma.
    Liu D; Wang L; Li H; Li D; Zhou J; Wang J; Zhang Q; Cai D
    Molecules; 2024 Jan; 29(3):. PubMed ID: 38338418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thermo- and pH-responsive targeted lipid-coated mesoporous nano silica platform for dual delivery of paclitaxel and gemcitabine to overcome HER2-positive breast cancer.
    Nasri N; Saharkhiz S; Dini G; Yousefnia S
    Int J Pharm; 2023 Dec; 648():123606. PubMed ID: 37972671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivering hydrophilic and hydrophobic chemotherapeutics simultaneously by magnetic mesoporous silica nanoparticles to inhibit cancer cells.
    Liu Q; Zhang J; Sun W; Xie QR; Xia W; Gu H
    Int J Nanomedicine; 2012; 7():999-1013. PubMed ID: 22403484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice.
    Meng H; Zhao Y; Dong J; Xue M; Lin YS; Ji Z; Mai WX; Zhang H; Chang CH; Brinker CJ; Zink JI; Nel AE
    ACS Nano; 2013 Nov; 7(11):10048-65. PubMed ID: 24143858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading paclitaxel and tanshinone IIA for the treatment of acute promyelocytic leukemia.
    Li Z; Zhang Y; Zhu C; Guo T; Xia Q; Hou X; Liu W; Feng N
    Int J Pharm; 2020 Aug; 586():119576. PubMed ID: 32603839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs.
    Xia T; Kovochich M; Liong M; Meng H; Kabehie S; George S; Zink JI; Nel AE
    ACS Nano; 2009 Oct; 3(10):3273-86. PubMed ID: 19739605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming multiple gastrointestinal barriers by bilayer modified hollow mesoporous silica nanocarriers.
    Wang Y; Zhao Y; Cui Y; Zhao Q; Zhang Q; Musetti S; Kinghorn KA; Wang S
    Acta Biomater; 2018 Jan; 65():405-416. PubMed ID: 29037897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PEGylated Lipid bilayer coated mesoporous silica nanoparticles for co-delivery of paclitaxel and curcumin: Design, characterization and its cytotoxic effect.
    Lin J; Cai Q; Tang Y; Xu Y; Wang Q; Li T; Xu H; Wang S; Fan K; Liu Z; Jin Y; Lin D
    Int J Pharm; 2018 Jan; 536(1):272-282. PubMed ID: 29079221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer.
    Slapak EJ; El Mandili M; Brink MST; Kros A; Bijlsma MF; Spek CA
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced efficacy and drug delivery with lipid coated mesoporous silica nanoparticles in cancer therapy.
    Amin MU; Ali S; Ali MY; Tariq I; Nasrullah U; Pinnapreddy SR; Wölk C; Bakowsky U; Brüßler J
    Eur J Pharm Biopharm; 2021 Aug; 165():31-40. PubMed ID: 33962002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAPN2-responsive mesoporous silica nanoparticles: A promising nanocarrier for targeted therapy of pancreatic cancer.
    Slapak EJ; El Mandili M; Ten Brink MS; Kros A; Bijlsma MF; Spek CA
    Cancer Lett; 2024 May; 590():216845. PubMed ID: 38589004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aptamer Tethered Bio-Responsive Mesoporous Silica Nanoparticles for Efficient Targeted Delivery of Paclitaxel to Treat Ovarian Cancer Cells.
    Salve R; Kumar P; Chaudhari BP; Gajbhiye V
    J Pharm Sci; 2023 May; 112(5):1450-1459. PubMed ID: 36669561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acidity and Glutathione Dual-Responsive Polydopamine-Coated Organic-Inorganic Hybrid Hollow Mesoporous Silica Nanoparticles for Controlled Drug Delivery.
    Chen Q; Chen Y; Zhang W; Huang Q; Hu M; Peng D; Peng C; Wang L; Chen W
    ChemMedChem; 2020 Oct; 15(20):1940-1946. PubMed ID: 32762008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodegradable, pH-Sensitive Hollow Mesoporous Organosilica Nanoparticle (HMON) with Controlled Release of Pirfenidone and Ultrasound-Target-Microbubble-Destruction (UTMD) for Pancreatic Cancer Treatment.
    Gao F; Wu J; Niu S; Sun T; Li F; Bai Y; Jin L; Lin L; Shi Q; Zhu LM; Du L
    Theranostics; 2019; 9(20):6002-6018. PubMed ID: 31534533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances in Mesoporous Silica Nanoparticles for Targeted Drug Delivery Applications.
    Abu-Dief AM; Alsehli M; Al-Enizi A; Nafady A
    Curr Drug Deliv; 2022; 19(4):436-450. PubMed ID: 34238185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of lactoferrin mesoporous silica nanoparticles for pemetrexed/ellagic acid synergistic breast cancer therapy.
    Ali OM; Bekhit AA; Khattab SN; Helmy MW; Abdel-Ghany YS; Teleb M; Elzoghby AO
    Colloids Surf B Biointerfaces; 2020 Apr; 188():110824. PubMed ID: 32023511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.